Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)

← catalyst calendar

NCT04550962

Sponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.

Phase
Status
Completed
Study type
Observational
Enrollment
376actual
Sites
41
Countries
Argentina, Chile, Colombia +9

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2020-11-02actualWhen the study began enrolling
Primary completion2026-06-18actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2026-06-18actualThe whole study's end, after follow-up
First posted2020-09-16actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-07-20actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Asthma

Intervention

  • Drug: Dupilumab SAR231893 — also filed as Dupixent

Primary outcomes

what the primary-completion date above is the date OF
Baseline Characteristics: Socio-demographics
measured At baseline
Baseline Characteristics: Medical history
measured At baseline
Baseline Characteristics: Disease characteristics
measured At baseline
Baseline Characteristics: Biomarkers
measured At baseline
Baseline Characteristics: Concomitant treatments for asthma
measured At baseline

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed